Ardelyx Inc is a biopharmaceutical company focused on developing innovative treatments for gastrointestinal and cardiorenal diseases. Its flagship product, tenapanor, aims to alleviate symptoms of irritable bowel syndrome with constipation. Additionally, Ardelyx is advancing treatments for chronic kidney disease and related conditions, including a therapy to manage serum phosphorus levels and another targeting elevated serum potassium. With partnerships in various territories, Ardelyx is committed to addressing significant unmet medical needs. Founded in 2007 and based in Waltham, Massachusetts, the company continues to expand its therapeutic portfolio.